Immune pathogenesis of heparin-induced thrombocytopenia

Summary

The immune response to heparin is one of the most common drug-induced allergies, and yet, atypical for a drug hypersensitivity reaction. Whereas most drug-induced allergies are rare, idiosyncratic and lifelong, the allergic response to heparin is common, predictable in certain clinical settings and transient. Advances in the last decade with regards to structural characterisation of the PF4/heparin antigenic complex, contributions of innate immunity and development of animal models have provided insights into the distinctive features of the HIT immune response. Recent descriptions of the crystal structure of the PF4/heparin complex, alongside other biophysical studies, have clarified the structural requirements for immunogenicity and heparin-dependency of antibody formation. Studies of interactions of PF4 with bacterial cell walls as well as epidemiologic associations of anti-PF4/heparin antibody formation and infection suggest a role for immune priming and explain the rapid evolution of an isotype-switched immune response in sensitised patients. Murine models have greatly facilitated investigations of cellular basis of the HIT response and identified a major role for T-cells and marginal zone B-cells, but key findings have yet to be validated in human disease. This chapter will summarise recent investigations of the HIT immune response in the context of major pathways of immune activation and identify areas of uncertainty.

Keywords

Heparin-induced thrombocytopenia - platelet factor 4 - heparin - murine models

• References

• 1 Hursting MJ, Pai P, McCracken JE. et al. Platelet Factor 4/Heparin Antibodies in Blood Bank Donors. Am J Clin Pathol 2010; 134: 774-780.
• 2 Krauel K, Potschke C, Weber C. et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378.
• 3 Warkentin TE, Makris M, Jay RM. et al. A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. Amer J Med 2008; 121: 632-636.
• 4 Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT?. J Thromb Haemost 2008; 06: 1598-1600.
• 5 Warkentin TE, Basciano PA, Knopman J. et al. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123: 3651-3654.
• 6 Pruthi RK, Daniels PR, Nambudiri GS. et al. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT. J Thromb Haemost 2009; 07: 499-501.
• 7 Ketha S, Smithedajkul P, Vella A. et al. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost 2013; 109: 669-675.
• 8 Okata T, Miyata S, Miyashita F. et al. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: Atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2015; 26: 602-607.
• 9 Bito S, Miyata S, Migita K. et al. Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery. Blood 2016; 127: 1036-1043.
• 10 Warkentin TE. Knee replacement and HIT without heparin. Blood 2016; 127: 961-962.
• 11 Bauer TL, Arepally G, Konkle BA. et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-1246.
• 12 Visentin GP, Malik M, Cyganiak KA. et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med 1996; 128: 376-383.
• 13 Pouplard C, May MA, Iochmann S. et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536.
• 14 Trossaert M, Gaillard A, Commin PL. et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101: 653-655.
• 15 Amiral J, Peynaud-Debayle E, Wolf M. et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996; 52: 90-95.
• 16 Girolami B, Prandoni P, Stefani PM. et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955-2959.
• 17 Obeng EA, Harney KM, Moniz T. et al. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr 2015; 166: 144-150.
• 18 Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther 2012; 17: 12-30.
• 19 Fausett MB, Vogtlander M, Lee RM. et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185: 148-152.
• 20 Greinacher A, Kohlmann T, Strobel U. et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
• 21 Warkentin TE, Sheppard JA, Moore JC. et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969.
• 22 Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
• 23 Rice L, Attisha WK, Drexler A. et al. Delayed-Onset Heparin-induced Thrombocytopenia. Ann Intern Med 2002; 136: 210-215.
• 24 Cines DB, Kaywin P, Bina M. et al. Heparin-associated thrombocytopenia. N Engl J Med 1980; 303: 788-795.
• 25 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
• 26 Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343: 515.
• 27 Lubenow N, Kempf R, Eichner A. et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37-42.
• 28 Warkentin TE, Sheppard J-AI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are re-exposed to heparin. Blood 2014; 123: 2485-2493.
• 29 Selleng K, Schutt A, Selleng S. et al. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 2010; 50: 32-39.
• 30 Greinacher A, Potzsch B, Amiral J. et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterisation of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251.
• 31 Rauova L, Poncz M, McKenzie SE. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
• 32 Greinacher A, Gopinadhan M, Gunther J-U. et al. Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralisation Forms the Antigens Recognized by HIT Antibodies. Arterioscler Thromb Vasc Biol 2006; 26: 2386-2393.
• 33 Suvarna S, Espinasse B, Qi R. et al. Determinants of PF4/heparin immunogeneicity. Blood 2007; 110: 4253-4260.
• 34 Brandt S, Krauel K, Gottschalk KE. et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost 2014; 112: 53-64.
• 35 Kreimann M, Brandt S, Krauel K. et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124: 2442-2449.
• 36 Cai Z, Yarovoi SV, Zhu Z. et al. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nat Commun 2015; 06: 8277.
• 37 Arepally GM, Kamei S, Park KS. et al. Characterisation of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 2000; 95: 1533-1540.
• 38 Zhang X, Chen L, Bancroft DP. et al. Crystal structure of recombinant human platelet factor 4. Biochemistry 1994; 33: 8361-8366.
• 39 Huhle G, Harenberg J, Malsch R. et al. Monoclonal antibodies against heparin and heparinoids. Semin Thromb Hemost 1997; 23: 17-22.
• 40 Gitel S, Medina V, Wessler S. Preparation and identification of a population of antibodies that recognize carbodiimide-modified heparin. Blood 1985; 65: 902-911.
• 41 Suvarna S, Rauova L, McCracken EK. et al. PF4/heparin complexes are T cell-dependent antigens. Blood 2005; 106: 929-931.
• 42 Chudasama SL, Espinasse B, Hwang F. et al. Heparin modifies the immunogenicity of positively-charged proteins. Blood 2010; 116: 6046-6053.
• 43 Krauel K, Weber C, Brandt S. et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120: 3345-3352.
• 44 Brandt S, Krauel K, Jaax M. et al. Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. Thromb Haemost 2015; 114: 1189-1198.
• 45 Greinacher A, Holtfreter B, Krauel K. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401.
• 46 Pongas G, Dasgupta SK, Thiagarajan P. Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. Thromb Res 2013; 132: 217-220.
• 47 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunisation. J Thromb Haemost 2010; 08: 504-512.
• 48 Pandey S, Kawai T, Akira S. Microbial Sensing by Toll-Like Receptors and Intracellular Nucleic Acid Sensors. Cold Spring Harb Perspect Biol 2015; 07: 1-18.
• 49 O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 07: 353-364.
• 50 Suvarna S, Qi R, Hollingsworth JW. et al. Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway. Br J Haematol 2008; 142: 671-673.
• 51 Prechel MM, Walenga JM. Complexes of platelet factor 4 and heparin activate Toll-like receptor 4. J Thromb Haemost 2015; 13: 665-670.
• 52 Potschke C, Selleng S, Broker BM. et al. Heparin-induced thrombocytopenia: further evidence for a unique immune response. Blood 2012; 120: 4238-4245.
• 53 Bacsi S, De Palma R, Visentin GP. et al. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocy-topenia/thrombosis. Blood 1999; 94: 208-215.
• 54 Bakchoul T, Assfalg V, Zöllner H. et al. Anti-platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation. J Thromb Haemost 2014; 12: 871-878.
• 55 Zheng Y, Yu M, Padmanabhan A. et al. Critical role of CD4 T cells in PF4/heparin antibody production in mice. Blood 2015; 125: 1826-1829.
• 56 Sakaguchi S, Sakaguchi N, Shimizu J. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
• 57 Fleischer J, Grage-Griebenow E, Kasper B. et al. Platelet Factor 4 Inhibits Proliferation and Cytokine Release of Activated Human T Cells. J Immunol 2002; 169: 770-777.
• 58 Liu CY, Battaglia M, Lee SH. et al. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25− (nonregulatory) T cells. J Immunol 2005; 174: 2680-2686.
• 59 Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol 2016; 11: 137-154.
• 60 Zheng Y, Yu M, Podd A. et al. Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 2013; 121: 3484-3492.
• 61 Krauel K, Schulze A, Jouni R. et al. Further insights into the anti-PF4/heparin IgM immune response. Thromb Haemost 2016; 115: 752-761.
• 62 Zheng Y, Wang AW, Yu M. et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 2014; 123: 931-934.
• 63 Joglekar M, Khandelwal S, Cines DB. et al. Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages. J Thromb Haemost 2015; 13: 1416-1427.